ドラッグ＆遺伝子デリバリーデバイス市場：投与経路、方法、ベクター別-2025-2030年の世界予測

ドラッグ＆遺伝子デリバリーデバイス市場は、2023年に43億3,000万米ドルと評価され、2024年には47億9,000万米ドルに達すると予測され、CAGR 10.72%で成長し、2030年には88億3,000万米ドルに達すると予測されています。

ドラッグ＆遺伝子デリバリーデバイス市場には、医薬化合物や遺伝物質を患者の体内に直接送達し、副作用を最小限に抑えた標的治療を実現するために使用される幅広いシステムが含まれます。将来の展望は、これらの機器が慢性疾患や遺伝性疾患の個別化治療において極めて重要な役割を果たす精密医療の進展にあります。こうした医療機器の必要性は、慢性疾患や遺伝性疾患の有病率の高まりと、低侵襲の送達技術が重視されるようになったことに起因します。用途は、がん、糖尿病、感染症など治療分野によってさまざまであり、最終用途は病院、診療所、在宅医療などです。市場に影響を与える主な成長要因としては、バイオテクノロジーの進歩、生物製剤の需要拡大、送達効果と患者のコンプライアンスを高めるナノテクノロジーの革新などが挙げられます。最近の動向は、放出制御のために生理学的条件に反応する生分解性ドラッグデリバリーシステムやスマートドラッグデリバリーシステムの開発に潜在的な機会があることを示唆しています。

課題には、規制上のハードル、高い開発コスト、潜在的な生体適合性の問題などがあります。さらに、主要医薬品の特許切れや厳格な品質管理要件による制約もあります。市場競争は激しく、マイクロニードル、ハイドロゲル、遺伝子導入用非ウイルス性ベクターなどの送達メカニズムの改良に焦点を当てた研究開発には大きなビジネスチャンスがあります。利害関係者は、デバイスの機能性と患者の転帰を向上させるため、最先端技術と異業種コラボレーションへの投資が奨励されます。新たな機会を活用するため、企業は個別化送達システムの改善においてAIやビッグデータ解析を活用するためのパートナーシップを模索することができます。革新は、診断と治療機能を統合し、それによって有効性と患者のアドヒアランスを強化する多機能デリバリー・プラットフォームに焦点を当てるのが最善です。精密医療と生物製剤の進化する状況は、継続的な研究とイノベーションを要求し、戦略的な市場参入ポイントと持続的な事業成長への道を開く。

市場力学：急速に進化するドラッグ＆遺伝子デリバリーデバイス市場の主要市場インサイトを公開

ドラッグ＆遺伝子デリバリーデバイス市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 心血管障害（CVDs）および生活習慣病の有病率の上昇
  • 自動注射器および先進肺装置のイントロダクション
  • 医薬品および治療用医薬品の消費量の増加
• 市場抑制要因
  • 合併症の増加、治療薬や医薬品の送達に必要な専門知識
• 市場機会
  • スマートナノ粒子技術、リポソーム＆ハイドロゲル、3次元印刷など、ドラッグデリバリーおよび遺伝子デリバリーシステムの分野における進歩
  • 遺伝子送達システム開発のためのゲノミクス分野における継続的研究開発の増加
• 市場の課題
  • ハイエンド製品のコスト上昇

ポーターの5つの力：ドラッグ＆遺伝子デリバリーデバイス市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：ドラッグ＆遺伝子デリバリーデバイス市場における外部からの影響の把握

外部マクロ環境要因は、ドラッグ＆遺伝子デリバリーデバイス市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析ドラッグ＆遺伝子デリバリーデバイス市場における競合情勢の把握

ドラッグ＆遺伝子デリバリーデバイス市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスドラッグ＆遺伝子デリバリーデバイス市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、ドラッグ＆遺伝子デリバリーデバイス市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨ドラッグ＆遺伝子デリバリーデバイス市場における成功への道筋を描く

ドラッグ＆遺伝子デリバリーデバイス市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報に基づいた意思決定を行う上で役立つ重要な質問にも回答しています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 心血管疾患（CVD）および生活習慣病の有病率の上昇
    • 自動注射器と先進的な肺デバイスのイントロダクション
    • 医薬品および治療用医薬品の消費量の増加
  • 抑制要因
    • 治療薬や薬剤の提供に求められる複雑さと専門知識の増加
  • 機会
    • スマートナノ粒子技術、リポソームとハイドロゲル、3次元印刷などの薬物および遺伝子送達システムの分野における進歩
    • 遺伝子送達システムの開発のためのゲノミクス分野における継続的な研究開発の増加
  • 課題
    • 高級品のコスト上昇
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 ドラッグ＆遺伝子デリバリーデバイス市場：投与経路別

• 吸入
• 注射可能
• 鼻腔
• 眼科
• オーラル
• 話題
• 経皮

第7章 ドラッグ＆遺伝子デリバリーデバイス市場：方法別

• 生体外
• 現地

第8章 ドラッグ＆遺伝子デリバリーデバイス市場ベクター

• 非ウイルス性
• バイラル

第9章 南北アメリカのドラッグ＆遺伝子デリバリーデバイス市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域のドラッグ＆遺伝子デリバリーデバイス市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカのドラッグ＆遺伝子デリバリーデバイス市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• 3M Company
• Antares Pharma, Inc.
• B. Braun SE
• Baxter International Inc.
• Becton, Dickinson and Company
• Eisai Co., Ltd.
• Enable Injections, Inc.
• Gerresheimer AG
• Insulet Corporation
• Johnson & Johnson Services Inc.
• Koninklijke Philips N.V.
• Merck KGaA
• OraSure Technologies, Inc.
• Oxford BioMedica PLC
• Sanofi S.A.

LIST OF FIGURES

• FIGURE 1. DRUG & GENE DELIVERY DEVICES MARKET RESEARCH PROCESS
• FIGURE 2. DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. DRUG & GENE DELIVERY DEVICES MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. DRUG & GENE DELIVERY DEVICES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. DRUG & GENE DELIVERY DEVICES MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. DRUG & GENE DELIVERY DEVICES MARKET DYNAMICS
• TABLE 7. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY INHALATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NASAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY OCULAR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY EX VIVO, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY IN SITU, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON-VIRAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 26. ARGENTINA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 29. BRAZIL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 30. BRAZIL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
• TABLE 31. CANADA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 32. CANADA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 33. CANADA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
• TABLE 34. MEXICO DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 35. MEXICO DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 36. MEXICO DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 39. UNITED STATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
• TABLE 40. UNITED STATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 43. ASIA-PACIFIC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
• TABLE 44. ASIA-PACIFIC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 45. AUSTRALIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 46. AUSTRALIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 47. AUSTRALIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
• TABLE 48. CHINA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 49. CHINA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 50. CHINA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
• TABLE 51. INDIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 52. INDIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 53. INDIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
• TABLE 54. INDONESIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 55. INDONESIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 56. INDONESIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
• TABLE 57. JAPAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 58. JAPAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 59. JAPAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
• TABLE 60. MALAYSIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 61. MALAYSIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 62. MALAYSIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
• TABLE 63. PHILIPPINES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 64. PHILIPPINES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 65. PHILIPPINES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
• TABLE 66. SINGAPORE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 67. SINGAPORE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 68. SINGAPORE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
• TABLE 69. SOUTH KOREA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 70. SOUTH KOREA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 71. SOUTH KOREA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
• TABLE 72. TAIWAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 73. TAIWAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 74. TAIWAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
• TABLE 75. THAILAND DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 76. THAILAND DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 77. THAILAND DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
• TABLE 78. VIETNAM DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 79. VIETNAM DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 80. VIETNAM DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 83. EUROPE, MIDDLE EAST & AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
• TABLE 84. EUROPE, MIDDLE EAST & AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 85. DENMARK DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 86. DENMARK DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 87. DENMARK DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
• TABLE 88. EGYPT DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 89. EGYPT DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 90. EGYPT DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
• TABLE 91. FINLAND DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 92. FINLAND DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 93. FINLAND DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
• TABLE 94. FRANCE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 95. FRANCE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 96. FRANCE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
• TABLE 97. GERMANY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 98. GERMANY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 99. GERMANY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
• TABLE 100. ISRAEL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 101. ISRAEL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 102. ISRAEL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
• TABLE 103. ITALY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 104. ITALY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 105. ITALY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
• TABLE 106. NETHERLANDS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 107. NETHERLANDS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 108. NETHERLANDS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
• TABLE 109. NIGERIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 110. NIGERIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 111. NIGERIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
• TABLE 112. NORWAY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 113. NORWAY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 114. NORWAY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
• TABLE 115. POLAND DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 116. POLAND DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 117. POLAND DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
• TABLE 118. QATAR DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 119. QATAR DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 120. QATAR DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
• TABLE 121. RUSSIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 122. RUSSIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 123. RUSSIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
• TABLE 124. SAUDI ARABIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 125. SAUDI ARABIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 126. SAUDI ARABIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 129. SOUTH AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
• TABLE 130. SPAIN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 131. SPAIN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 132. SPAIN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
• TABLE 133. SWEDEN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 134. SWEDEN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 135. SWEDEN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
• TABLE 136. SWITZERLAND DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 137. SWITZERLAND DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 138. SWITZERLAND DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
• TABLE 139. TURKEY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 140. TURKEY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 141. TURKEY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
• TABLE 142. UNITED ARAB EMIRATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 143. UNITED ARAB EMIRATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 144. UNITED ARAB EMIRATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
• TABLE 145. UNITED KINGDOM DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 146. UNITED KINGDOM DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 147. UNITED KINGDOM DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
• TABLE 148. DRUG & GENE DELIVERY DEVICES MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 149. DRUG & GENE DELIVERY DEVICES MARKET, FPNV POSITIONING MATRIX, 2023

The Drug & Gene Delivery Devices Market was valued at USD 4.33 billion in 2023, expected to reach USD 4.79 billion in 2024, and is projected to grow at a CAGR of 10.72%, to USD 8.83 billion by 2030.

The market for Drug & Gene Delivery Devices encompasses a wide range of systems used to deliver pharmaceutical compounds and genetic materials directly into a patient's system, ensuring targeted therapy with minimal side effects. Future scope lies in advancing precision medicine, where these devices could become pivotal in personalized treatments for chronic and genetic diseases. The necessity for these devices stems from the growing prevalence of chronic and genetic disorders and an increasing emphasis on minimally invasive delivery techniques. Applications vary across therapeutic areas, including oncology, diabetes, and infections, with end-use segments covering hospitals, clinics, and home care settings. Key growth factors influencing the market include advancements in biotechnology, growing demand for biologics, and innovations in nanotechnology which enhance delivery efficacy and patient compliance. Recent trends suggest potential opportunities in developing biodegradable and smart drug delivery systems that respond to physiological conditions for controlled release.

Challenges include regulatory hurdles, high development costs, and potential biocompatibility issues. Limitations are further imposed by patent expirations of major drugs and stringent quality control requirements. The market exhibits a competitive nature, with substantial opportunities in research and development focused on improving delivery mechanisms such as micro-needles, hydrogels, and non-viral vectors for gene delivery. Stakeholders are encouraged to invest in cutting-edge technologies and cross-industry collaborations to enhance device functionality and patient outcomes. To capitalize on emerging opportunities, firms can explore partnerships for leveraging AI and big data analytics in improving personalized delivery systems. Innovations are best focused on multifunctional delivery platforms that integrate diagnostics and therapeutic functions, thereby strengthening efficacy and patient adherence. The evolving landscape in precision medicine and biologics demands continuous research and innovation, paving the way for strategic market entry points and sustained business growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Drug & Gene Delivery Devices Market

The Drug & Gene Delivery Devices Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rise in the prevalence rate of cardiovascular disorders (CVDs) and lifestyle disorders
  • Introduction of auto-injectors and advanced pulmonary devices
  • Rise in the consumption of drugs and therapeutic pharmaceuticals
• Market Restraints
  • Increase in complications and expertise required in delivering therapeutics and drugs
• Market Opportunities
  • Advancements in the field of drug and gene delivery systems such as smart nanoparticle technology, liposomes & hydrogels, and three-dimensional printing
  • Increasing ongoing research and development in the field of genomics for the development of gene delivery systems
• Market Challenges
  • Increasing cost of high-end products

Porter's Five Forces: A Strategic Tool for Navigating the Drug & Gene Delivery Devices Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Drug & Gene Delivery Devices Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Drug & Gene Delivery Devices Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Drug & Gene Delivery Devices Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Drug & Gene Delivery Devices Market

A detailed market share analysis in the Drug & Gene Delivery Devices Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Drug & Gene Delivery Devices Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Drug & Gene Delivery Devices Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Drug & Gene Delivery Devices Market

A strategic analysis of the Drug & Gene Delivery Devices Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Drug & Gene Delivery Devices Market, highlighting leading vendors and their innovative profiles. These include 3M Company, Antares Pharma, Inc., B. Braun SE, Baxter International Inc., Becton, Dickinson and Company, Eisai Co., Ltd., Enable Injections, Inc., Gerresheimer AG, Insulet Corporation, Johnson & Johnson Services Inc., Koninklijke Philips N.V., Merck KGaA, OraSure Technologies, Inc., Oxford BioMedica PLC, and Sanofi S.A..

Market Segmentation & Coverage

This research report categorizes the Drug & Gene Delivery Devices Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Route of Administration, market is studied across Inhalation, Injectable, Nasal, Ocular, Oral, Topical, and Transdermal.
• Based on Method, market is studied across Ex vivo and In situ.
• Based on Vector, market is studied across Non-viral and Viral.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rise in the prevalence rate of cardiovascular disorders (CVDs) and lifestyle disorders
    • 5.1.1.2. Introduction of auto-injectors and advanced pulmonary devices
    • 5.1.1.3. Rise in the consumption of drugs and therapeutic pharmaceuticals
  • 5.1.2. Restraints
    • 5.1.2.1. Increase in complications and expertise required in delivering therapeutics and drugs
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancements in the field of drug and gene delivery systems such as smart nanoparticle technology, liposomes & hydrogels, and three-dimensional printing
    • 5.1.3.2. Increasing ongoing research and development in the field of genomics for the development of gene delivery systems
  • 5.1.4. Challenges
    • 5.1.4.1. Increasing cost of high-end products
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Drug & Gene Delivery Devices Market, by Route of Administration

• 6.1. Introduction
• 6.2. Inhalation
• 6.3. Injectable
• 6.4. Nasal
• 6.5. Ocular
• 6.6. Oral
• 6.7. Topical
• 6.8. Transdermal

7. Drug & Gene Delivery Devices Market, by Method

• 7.1. Introduction
• 7.2. Ex vivo
• 7.3. In situ

8. Drug & Gene Delivery Devices Market, by Vector

• 8.1. Introduction
• 8.2. Non-viral
• 8.3. Viral

9. Americas Drug & Gene Delivery Devices Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Drug & Gene Delivery Devices Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Drug & Gene Delivery Devices Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. 3M Company
• 2. Antares Pharma, Inc.
• 3. B. Braun SE
• 4. Baxter International Inc.
• 5. Becton, Dickinson and Company
• 6. Eisai Co., Ltd.
• 7. Enable Injections, Inc.
• 8. Gerresheimer AG
• 9. Insulet Corporation
• 10. Johnson & Johnson Services Inc.
• 11. Koninklijke Philips N.V.
• 12. Merck KGaA
• 13. OraSure Technologies, Inc.
• 14. Oxford BioMedica PLC
• 15. Sanofi S.A.